Patient [20, 35] Proteins with a consistent change in expression in biofluids from ALS patients across two or more proteomic studies are shown. The protein name is given, followed by the official gene symbol in brackets. Up [20] Zinc-Alpha-2-Glycoprotein (AZGP1) 2 Down [20] Up [36] Proteins that showed contradictory change in expression in biofluids from ALS patients in two or more proteomic studies. Protein name is given, followed by official gene symbol in brackets. Direction of differential expression and number of studies that identified protein changes are shown (studies are listed in the reference column). * CysGly-transthyretin-Modified form of transthyretin generated by oxidative damage. Proteins that showed consistent direction of differential expression in cells and tissues in at least two proteomic studies of ALS. Proteins are listed according to direction of differential expression (proteins with increased expression are listed first, followed by proteins with decreased expression). Protein name is given, followed by official gene symbol in brackets. ALS model and sample type used in each study are listed, together with the number of studies that identified protein changes (studies are listed in the reference column). Isocitrate Dehydrogenase 3 (NAD+) Beta (IDH3B) [58] [57] Heat Shock Protein 90, Beta (Grp94), Member 1 (HSP90B1) [54] [47] Mitogen-Activated Protein Kinase 1 (MAPK1) [54] [47] Lon Peptidase 1 (LONP1) [44] [57] Dynamin 1 (DNM1) [52, 62] [60] 2,4-Dienoyl Coa Reductase 1 (DECR1) [58] [44]
Proteins that showed contradictory direction of differential expression in cells and tissues in at least two proteomic studies of ALS. Protein name is given, followed by official gene symbol in brackets. Studies that identified increased or decreased protein expression are listed in column two and three. 
